|
1）Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74
|
|
|
|
2）Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013; 31: 1039-49
|
|
|
|
|
|
3）Weinstein IB. Cancer. Addiction to oncogenes－the Achilles heal of cancer. Science. 2002; 297: 63-4
|
|
|
|
|
|
4）Mardis ER. The impact of next-generation sequencing technology on genetics. Trends Genet. 2008; 24: 133-41
|
|
|
|
|
|
5）Shaffer C. Next-generation sequencing outpaces expectations. Nat Biotechnol. 2007; 25: 149
|
|
|
|
|
|
6）Reumers J, De Rijk P, Zhao H, et al. Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nat Biotechnol. 2011; 30: 61-8
|
|
|
|
|
|
7）Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-39
|
|
|
|
|
|
8）Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-500
|
|
|
|
|
|
9）Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101: 13306-11
|
|
|
|
|
|
10）Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-57
|
|
|
|
|
|
11）Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-6
|
|
|
|
|
|
12）Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-703
|
|
|
|
|
|
13）Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013; 14: 590-8
|
|
|
|
|
|
14）Mazières J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013; 31: 1997-2003
|
|
|
|
|
|
15）Jänne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013; 14: 38-47
|
|
|
|
|
|
16）Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011; 29: 3574-9
|
|
|
|
|
|
17）Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008; 68: 5524-8
|
|
|
|
|
|
18）Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009; 27: 1667-74
|
|
|
|
|
|
19）Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316: 1039-43
|
|
|
|
|
|
20）Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008; 68: 9479-87
|
|
|
|
|
|
21）Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012; 18: 375-7
|
|
|
|
|
|
22）Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18: 378-81
|
|
|
|
|
|
23）Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012; 18: 382-4
|
|
|
|
|
|
24）Ji H, Zhao X, Yuza Y, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A. 2006; 103: 7817-22
|
|
|
|
|
|
25）Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489: 519-25
|
|
|
|
|
|
26）Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinasegene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011; 1: 78-89
|
|
|
|
|
|
27）Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013; 19: 1469-72
|
|
|
|
|
|
28）Berger AH, Imielinski M, Duke F, et al. Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene. 2014; 33: 4418-23
|
|
|
|
|
|
29）Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014; 124: 1582-6
|
|
|
|
|
|
30）Fernandez-Cuesta L, Plenker D, Osada H, et al. CD74-NRG1 Fusions in Lung Adenocarcinoma. Cancer Discov. 2014; 4: 415-22
|
|
|
|
|
|
31）Nakaoku T, Tsuta K, Ichikawa H, et al. Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma. Clin Cancer Res. 2014; 20: 3087-93
|
|
|
|
|
|
32）Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455: 1069-75
|
|
|
|
|
|
33）Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511: 543-50
|
|
|
|
|
|
34）Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013; 497: 108-12
|
|
|
|
|
|
35）Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012; 486: 532-6
|
|
|
|
|